After three years of embracing artificial intelligence across its global operations, Johnson & Johnson (J&J) has discovered that a small portion of its AI projects are delivering the lion’s share of the value.
According to a recent report from The Wall Street Journal, the healthcare and MedTech giant encouraged employees to explore nearly 900 AI use cases. The results? Roughly 10% to 15% of those initiatives are responsible for delivering 80% of the total business value.
Now, the company is pivoting its strategy. J&J is shifting focus and resources toward its most promising AI projects while cutting those that haven’t delivered meaningful returns.
“We’re prioritizing, we’re scaling, we’re looking at the things that make the most sense,”
— Jim Swanson, Chief Information Officer, Johnson & Johnson
High-Impact AI Use Cases at J&J
Among the standout success stories are:
- A Generative AI Copilot that helps sales teams fine-tune their conversations with healthcare professionals.
- An AI-powered internal chatbot that streamlines HR and company policy questions for employees.
- AI tool for drug discovery, designed to accelerate research and development timelines.
- A supply chain risk mitigation system that uses AI to predict and prevent disruptions.
This evolution signals a maturing approach to enterprise AI adoption. According to Swanson, the initial wide-net strategy was essential to help the organization get comfortable with AI’s capabilities. But now, the focus has shifted toward projects that are scalable, measurable, and impactful.
AI Proving Its Worth in Healthcare
J&J’s findings align with a broader trend across the healthcare sector. A PYMNTS Intelligence report found that 90% of healthcare executives in billion-dollar organizations reported a positive return on investment (ROI) from generative AI initiatives.
The most common and effective applications?
- Product and service innovation
- Automated, real-time customer service responses
Other major players are also making big AI bets. Apple is reportedly developing an AI-powered medical advice agent, while startups like Suki and tech giants like Microsoft are racing to launch new AI tools tailored for clinicians and researchers.
Johnson & Johnson’s data-driven approach offers a valuable lesson for any enterprise looking to integrate AI: experimentation is necessary, but long-term success lies in focusing on the few, high-impact use cases that drive measurable business outcomes.
Get the Latest AI News on AI Content Minds Blog